SPSathit Pichyangkul

Sathit Pichyangkul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sathit Pichyangkul has a total of 133 co-authors. Here are the top co-authors by number of shared publications:

  • Kosol Yongvanitchit

    Department of Bacterial and Parasitic Diseases, WRAIR-AFRIMS, Bangkok 10400, Thailand

    10 shared publications
  • Utaiwan Kum-Arb

    Department of Bacterial and Parasitic Diseases, WRAIR-AFRIMS, Bangkok 10400, Thailand

    9 shared publications
  • Amporn Limsalakpetch

    Department of Bacterial and Parasitic Diseases, WRAIR-AFRIMS, Bangkok 10400, Thailand

    6 shared publications
  • Carl Jeffries Mason

    Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

    4 shared publications
  • Rawiwan Im-Erbsin

    Department of Bacterial and Parasitic Diseases, WRAIR-AFRIMS, Bangkok 10400, Thailand

    4 shared publications
  • Suwimon Wiboon-Ut

    Department of Microbiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand

    4 shared publications

Latest Publications

  • Open Access

    mRNA-LNP vaccine encoding the Plasmodium vivax circumsporozoite protein is highly immunogenic and confers protection in mice

    by Amporn Limsalakpetch, Utaiwan Kum-Arb, Kosol Yongvanitchit, Rawiwan Im-Erbsin, Ratawan Ubalee, Norman Waters, Brian A. Vesely, Hiromi Muramatsu, Drew Weissman, Ying K. Tam, et al.


  • Open Access

    Superior protection in a relapsing Plasmodium cynomolgi rhesus macaque model by a chemoprophylaxis with sporozoite immunization regimen with atovaquone-proguanil followed by primaquine

    by Kosol Yongvanitchit, Utaiwan Kum-Arb, Amporn Limsalakpetch, Rawiwan Im-Erbsin, Ratawan Ubalee, Michele D. Spring, Brian A. Vesely, Norman Waters, Sathit Pichyangkul

    Background: To gain a deeper understanding of protective immunity against relapsing malaria, this study examined sporozoite-specific T cell responses induced by a chemoprophylaxis with sporozoite (CPS) immunization in a relapsing Plasmodium cynomolgi rhesus macaque model. Methods: The animals received three CPS immunizations with P. cynomolgi sporozoites, administered by mosquito bite, while under two anti-malarial drug regimens. Group 1 (n = 6) received artesunate/chloroquine (AS/CQ) followed by a radical cure with CQ plus primaquine (PQ). Group 2 (n = 6) received atovaquone-proguanil (AP) followed by PQ. After the final immunization, the animals were challenged with intravenous injection of 104P. cynomolgi sporozoites, the dose that induced reliable infection and relapse rate. These animals, along with control animals (n = 6), were monitored for primary infection and subsequent relapses. Immunogenicity blood draws were done after each of the three CPS session, before and after the challenge, with liver, spleen and bone marrow sampling and analysis done after the challenge. Results: Group 2 animals demonstrated superior protection, with two achieving protection and two experiencing partial protection, while only one animal in group 1 had partial protection. These animals displayed high sporozoite-specific IFN-γ T cell responses in the liver, spleen, and bone marrow after the challenge with one protected animal having the highest frequency of IFN-γ+ CD8+, IFN-γ+ CD4+, and IFN-γ+ γδ T cells in the liver. Partially protected animals also demonstrated a relatively high frequency of IFN-γ+ CD8+, IFN-γ+ CD4+, and IFN-γ+ γδ T cells in the liver. It is important to highlight that the second animal in group 2, which experienced protection, exhibited deficient sporozoite-specific T cell responses in the liver while displaying average to high T cell responses in the spleen and bone marrow. Conclusions: This research supports the notion that local liver T cell immunity plays a crucial role in defending against liver-stage infection. Nevertheless, there is an instance where protection occurs independently of T cell responses in the liver, suggesting the involvement of the liver's innate immunity. The relapsing P. cynomolgi rhesus macaque model holds promise for informing the development of vaccines against relapsing P. vivax.


  • Open Access

    Chemoprophylaxis with sporozoite immunization in P. knowlesi rhesus monkeys confers protection and elicits sporozoite-specific memory T cells in the liver

    by Sathit Pichyangkul, Michele D. Spring, Kosol Yongvanitchit, Utaiwan Kum-Arb, Amporn Limsalakpetch, Rawiwan Im-Erbsin, Ratawan Ubalee, Pattaraporn Vanachayangkul, Edmond J. Remarque, Evelina Angov, et al.

    Whole malaria sporozoite vaccine regimens are promising new strategies, and some candidates have demonstrated high rates of durable clinical protection associated with memory T cell responses. Little is known about the anatomical distribution of memory T cells following whole sporozoite vaccines, and immunization of nonhuman primates can be used as a relevant model for humans. We conducted a chemoprophylaxis with sporozoite (CPS) immunization in P. knowlesi rhesus monkeys and challenged via mosquito bites. Half of CPS immunized animals developed complete protection, with a marked delay in parasitemia demonstrated in the other half. Antibody responses to whole sporozoites, CSP, and AMA1, but not CelTOS were detected. Peripheral blood T cell responses to whole sporozoites, but not CSP and AMA1 peptides were observed. Unlike peripheral blood, there was a high frequency of sporozoite-specific memory T cells observed in the liver and bone marrow. Interestingly, sporozoite-specific CD4+ and CD8+ memory T cells in the liver highly expressed chemokine receptors CCR5 and CXCR6, both of which are known for liver sinusoid homing. The majority of liver sporozoite-specific memory T cells expressed CD69, a phenotypic marker of tissue-resident memory (TRM) cells, which are well positioned to rapidly control liver-stage infection. Vaccine strategies that aim to elicit large number of liver TRM cells may efficiently increase the efficacy and durability of response against pre-erythrocytic parasites.


  • Tissue Distribution of Memory T and B Cells in Rhesus Monkeys following Influenza A Infection

    by Sathit Pichyangkul, Kosol Yongvanitchit, Amporn Limsalakpetch, Utaiwan Kum-Arb, Rawiwan Im-Erbsin, Kobporn Boonnak, Arunee Thitithayanont, Anan Jongkaewwattana, Suwimon Wiboon-Ut, Duangrat Mongkolsirichaikul, et al.

    Studies of influenza-specific immune responses in humans have largely assessed systemic responses involving serum Ab and peripheral blood T cell responses. However, recent evidence indicates that tissue-resident memory T (TRM) cells play an important role in local murine intrapulmonary immunity. Rhesus monkeys were pulmonary exposed to 2009 pandemic H1N1 virus at days 0 and 28 and immune responses in different tissue compartments were measured. All animals were asymptomatic postinfection. Although only minimal memory immune responses were detected in peripheral blood, a high frequency of influenza nucleoprotein–specific memory T cells was detected in the lung at the “contraction phase,” 49–58 d after second virus inoculation. A substantial proportion of lung nucleoprotein-specific memory CD8+ T cells expressed CD103 and CD69, phenotypic markers of TRM cells. Lung CD103+ and CD103- memory CD8+ T cells expressed similar levels of IFN-γ and IL-2. Unlike memory T cells, spontaneous Ab secreting cells and memory B cells specific to influenza hemagglutinin were primarily observed in the mediastinal lymph nodes. Little difference in systemic and local immune responses against influenza was observed between young adult (6–8 y) and old animals (18–28 y). Using a nonhuman primate model, we revealed substantial induction of local T and B cell responses following 2009 pandemic H1N1 infection. Our study identified a subset of influenza-specific lung memory T cells characterized as TRM cells in rhesus monkeys. The rhesus monkey model may be useful to explore the role of TRM cells in local tissue protective immunity after rechallenge and vaccination.


  • Pre-Existing Cross-Reactive Antibodies to Avian Influenza H5N1 and 2009 Pandemic H1N1 in US Military Personnel

    by Sathit Pichyangkul, Somporn Krasaesub, Anan Jongkaewwattana, Arunee Thitithanyanont, Suwimon Wiboon-Ut, Kosol Yongvanitchit, Amporn Limsalakpetch, Utaiwan Kum-Arb, Duangrat Mongkolsirichaikul, Nuanpan Khemnu, et al.

    We studied cross-reactive antibodies against avian influenza H5N1 and 2009 pandemic (p) H1N1 in 200 serum samples from US military personnel collected before the H1N1 pandemic. Assays used to measure antibodies against viral proteins involved in protection included a hemagglutination inhibition (HI) assay and a neuraminidase inhibition (NI) assay. Viral neutralization by antibodies against avian influenza H5N1 and 2009 pH1N1 was assessed by influenza (H5) pseudotyped lentiviral particle-based and H1N1 microneutralization assays. Some US military personnel had cross-neutralizing antibodies against H5N1 (14%) and 2009 pH1N1 (16.5%). The odds of having cross-neutralizing antibodies against 2009 pH1N1 were 4.4 times higher in subjects receiving more than five inactivated whole influenza virus vaccinations than those subjects with no record of vaccination. Although unclear if the result of prior vaccination or disease exposure, these pre-existing antibodies may prevent or reduce disease severity.


  • Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage

    by Poonsook Keelapang, Narong Nitatpattana, Amporn Suphatrakul, Surat Punyahathaikul, Rungtawan Sriburi, Rojjanaporn Pulmanausahakul, Sathit Pichyangkul, Prida Malasit, Sutee Yoksan, Nopporn Sittisombut


  • Antiviral immune responses in H5N1-infected human lung tissue and possible mechanisms underlying the hyperproduction of interferon-inducible protein IP-10

    by Arunee Thitithanyanont, Anneke Engering, Monkol Uiprasertkul, Peeraya Ekchariyawat, Suwimon Wiboon-Ut, Romchat Kraivong, Amporn Limsalakpetch, Utaiwan Kum-Arb, Kosol Yongvanitchit, Noppadol Sa-Ard-Iam, et al.


  • Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys

    by S. Pichyangkul, P. Tongtawe, U. Kum-Arb, K. Yongvanitchit, M. Gettayacamin, M.R. Hollingdale, A. Limsalakpetch, V.A. Stewart, D.E. Lanar, S. Dutta, et al.


  • Open Access

    Cross-reactive Antibodies against Avian Influenza Virus A (H5N1)

    by Sathit Pichyangkul, Anan Jongkaewwattana, Arunee Thitithanyanont, Peeraya Ekchariyawat, Suwimon Wiboon-Ut, Amporn Limsalakpetch, Kosol Yongvanitchit, Utaiwan Kum-Arb, Rangsini Mahanonda, Pongsak Utaisincharoen, et al.

    Cross-reactive Antibodies against Avian Influenza Virus A (H5N1)


  • Preclinical Evaluation of the Safety and Immunogenicity of a Vaccine Consisting ofPlasmodium falciparumLiver-Stage Antigen 1 with Adjuvant AS01B Administered Alone or Concurrently with the RTS,S/AS01B Vaccine in Rhesus Primates

    by S. Pichyangkul, U. Kum-Arb, K. Yongvanitchit, A. Limsalakpetch, M. Gettayacamin, D. E. Lanar, L. A. Ware, V. A. Stewart, D. G. Heppner, P. Mettens, et al.

    Several lines of evidence suggest that targeting pre-erythrocytic-stage parasites for malaria vaccine development can provide sterile immunity. The objectives of this study were (i) to evaluate preclinically the safety and immunogenicity of a new recombinant pre-erythrocytic-stage antigen, liver-stage antigen 1 (LSA1), in nonhuman primates; and (ii) to investigate the potential for immune interference between LSA1 and the leading malaria vaccine candidate, RTS,S, by comparing the immune responses after single-antigen vaccination to responses after simultaneous administration of both antigens at separate sites. Using a rhesus monkey model, we found that LSA1 formulated with the GlaxoSmithKline proprietary adjuvant system AS01B (LSA1/AS01B) was safe and immunogenic, inducing high titers of antigen-specific antibody and CD4+T-cell responses, as monitored by the production of interleukin-2 and gamma interferon, using intracellular cytokine staining. RTS,S/AS01B vaccination was well tolerated and demonstrated robust antibody and moderate CD4+T-cell responses to circumsporozoite protein (CSP) and HBsAg. Positive CD8+T-cell responses to HBsAg were detected, whereas the responses to CSP and LSA1 were negligible. For both LSA1/AS01B and RTS,S/AS01B, no statistically significant differences were observed between individual and concurrent administration in the magnitude or duration of antibody and T-cell responses. Our results revealed that both pre-erythrocytic-stage antigens were safe and immunogenic, administered either separately or simultaneously to rhesus monkeys, and that no significant immune cross interference occurred with concurrent separate-site administration. The comparison of the profiles of immune responses induced by separate-site and single-site vaccinations with LSA1 and RTS,S warrants further investigation.